Oncofetal protein glypican-3 in testicular germ-cell tumor

Ota, Satoshi; Hishinuma, Michiyo; Yamauchi, Naoko; Goto, Akiteru; Morikawa, Teppei; Fujimura, Tetsuya; Kitamura, Tadaichi; Kodama, Tatsuhiko; Aburatani, Hiroyuki; Fukayama, Masashi

doi:10.1007/s00428-006-0238-x

Cited by 80 publications

(59 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody to glypican-3 is known to be a specific marker for YSTs. Ota et al (15) reported that glypican-3 was positive in all cases of YST and in some cases of CC, teratoma and syncytiotrophoblastic giant cells, but in no case of EC. This may suggest that DNMT3L-and AFP-expressing seminoma cells have a YST-like phenotype or have already differentiated to YST cells Third, when examined in the present mixed GCTs, DNMT3L expression was observed in various subtypes other than EC.…”

Section: Discussionmentioning

confidence: 99%

“…In an attempt to further clarify the phenotype of DNMT3L-positive seminoma cells, we conducted immunostaining with glypican-3, an oncofetal protein and a marker for extraembryonic differentiation, especially that of YSTs (15). In eight of the nine cases of DNMT3L-positive seminoma or seminoma elements examined, gypican-3 was negatively stained (Fig.…”

Section: Seminomasmentioning

confidence: 99%

See 1 more Smart Citation

DNA methyltransferase-3 like protein expression in various histological types of testicular germ cell tumor

Matsuoka

Kawai

Ando

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: DNA methyltransferase 3-like plays an important role in germ cell development. The aim of this study was to analyse the DNA methyltransferase 3-like protein expression in testicular germ cell tumors. Methods: The immunohistochemical expression of DNA methyltransferase 3-like was examined in 86 testicular germ cell tumor specimens in various clinical settings. The association between DNA methyltransferase 3-like expression and disease stage was analyzed. Results: DNA methyltransferase 3-like was strongly expressed in seven of the eight pure embryonal carcinomas (87.5%). Partial DNA methyltransferase 3-like expression was observed in 6 of 23 (26.1%) pure seminomas. Various degrees of DNA methyltransferase 3-like expression was observed in all four pure yolk sac tumors, of which three were prepubertal yolk sac tumors. In mixed germ cell tumors, DNA methyltransferase 3-like protein was expressed in various degrees in elements of the embryonal carcinoma (14/18, 77.8%), seminoma (4/11, 36.4%), teratoma (4/7, 57.1%) and choriocarcinoma (3/3, 100%) but not in the yolk sac tumors (0/4). When DNA methyltransferase 3-like expression was analyzed according to disease stages, it was significantly correlated with advanced seminoma rather than Stage I seminoma (46.2 vs. 0%, P = 0.019), whereas there was no significant difference in the DNA methyltransferase 3-like-positive proportion between Stage I and advanced disease in the mixed germ cell tumors. Conclusions: Our findings suggest that DNA methyltransferase 3-like protein may play roles not only in the development of embryonal carcinoma but also in the development of advanced pure seminoma and pure yolk sac tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Seminomasmentioning

confidence: 99%

DNA methyltransferase-3 like protein expression in various histological types of testicular germ cell tumor

Matsuoka

Kawai

Ando

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…32,[35][36][37] Recently, GPC3 has been reported to be overexpressed in testicular and ovarian yolk sac tumors. 25,26,32 Esheba et al reported that GPC3 immunohistochemistry is useful for distinguishing ovarian yolk sac tumors from clear cell adenocarcinomas because of the higher GPC3 expression in ovarian yolk sac tumors compared to clear cell adenocarcinomas. 32 Our results are similar to theirs in that most of yolk sac tumors showed diffuse GPC3 positivity, whereas only 10% of clear cell adenocarcinomas showed diffuse GPC3 positivity.…”

Section: 32mentioning

confidence: 99%

“…Its overexpression has been reported in certain types of tumors, such as hepatocellular carcinoma, 21,22 melanoma, 23 lung squamous cell carcinoma, 24 and testicular germ cell tumors. 25,26 GPC3 has also been reported to act as an immunohistochemical and serum marker for hepatocellular carcinoma and malignant melanoma. 21,23,27 In addition, it is now expected to be a potential target for immunotherapy against these neoplasms.…”

mentioning

confidence: 99%

Glypican-3 expression in clear cell adenocarcinoma of the ovary

et al. 2009

Self Cite

View full text Add to dashboard Cite

Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor. Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy. To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Mü llerian duct derivatives including endometrium in different menstrual phases. Among the benign lesions examined, glypican-3 expression was identified exclusively in the endometrial epithelium in the gestational period. A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied. Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; Po0.0001). All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3. In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate. However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases. Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.

show abstract

“…In addition to the traditionally known fetoprotein and CD30 [11], 3 recently identified germ cell tumor-associated markers (SALL4, glypican 3, and CDX2) have been found to be useful [12,13]. Glypican 3 is an oncofetal antigen that is expressed in yolk sac tumors (100%) Fig.…”

Section: Discussionmentioning

confidence: 97%